Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 25, 2021Orphanet Journal of Rare DiseasesOpen Access

New paradigms for the treatment of lysosomal storage diseases: targeting the endocannabinoid system as a therapeutic strategy

View Full Paper
Ask AI
Bookmark
Share

Authors

ESEdward H. SchuchmanIcahn School of Medicine at Mount SinaiMLMaría Dolores LedesmaCentro de Biología Molecular Severo OchoaCSCalogera M. SimonaroIcahn School of Medicine at Mount Sinai

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Schuchman et al. (2021) studied this question.

synapsesocial.com/papers/6ab4cbe357e145167e4d3e53https://doi.org/10.1186/s13023-021-01779-4
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1LYSOSOMAL STORAGE DISEASES1991 · 904 citations
  2. 2Systemic ceramide accumulation leads to severe and varied pathological consequences2013 · 107 citations
  3. 3Anandamide Revisited: How Cholesterol and Ceramides Control Receptor-Dependent and Receptor-Independent Signal Transmission Pathways of a Lipid Neurotransmitter2018 · 53 citations
  4. 4Gene Therapy, A Novel Therapeutic Tool for Neurological Disorders: Current Progress, Challenges and Future Prospective2020 · 37 citations
  5. 5Endocannabinoids and Liver Disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis2007 · 71 citations